← All trials
NCT05206513
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Aug 31, 2024
- First posted
- Jan 25, 2022
- Last posted
- Oct 13, 2022
- Enrollment
- 144
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Neurocrine BiosciencesLead sponsor
- Neurocrine BiosciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.